Search results for "Immuno-therapy"

showing 2 items of 2 documents

High-Intensity Focused Ultrasound- and Radiation Therapy-Induced Immuno-modulation: Comparison and Potential Opportunities

2017

In recent years, high-intensity focused ultrasound (HIFU) has emerged as a new and promising non-invasive and non-ionizing ablative technique for the treatment of localized solid tumors. Extensive pre-clinical and clinical studies have evidenced that, in addition to direct destruction of the primary tumor, HIFU-thermoablation may elicit long-term systemic host anti-tumor immunity. In particular, an important consequence of HIFU treatment includes the release of tumor-associated antigens (TAAs), the secretion of immuno-suppressing factors by cancer cells and the induction of cytotoxic T lymphocyte (CTL) activity. Radiation therapy (RT) is the main treatment modality used for many types of tu…

0301 basic medicinePathologymedicine.medical_specialtyRadiology Nuclear Medicine and ImagingAcoustics and Ultrasonicsmedicine.medical_treatmentBiophysicsImmunomodulation03 medical and health sciences0302 clinical medicineImmune systemNeoplasmsmedicineBystander effectHumansCancerChemotherapyRadiological and Ultrasound Technologybusiness.industryCancermedicine.diseasePrimary tumorThermal ablationHigh-intensity focused ultrasoundRadiation therapyImmuno-therapyRadiation therapyTumor vaccine030104 developmental biologyBiophysicHigh-intensity focused ultrasound030220 oncology & carcinogenesisCancer cellCancer researchHigh-Intensity Focused Ultrasound AblationAnti-tumor immunitybusinessAnti-tumor immunity; Cancer; High-intensity focused ultrasound; Immuno-therapy; Radiation therapy; Thermal ablation; Tumor vaccine
researchProduct

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

2020

Funding: Transgène; International audience; Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort and pre-clinical studies have established the link between a functional T-cell-mounted immunity and resolution of infection. TG1050 is an adenovirus 5-based vaccine that expresses HBV polymerase and domains of core and surface antigen and has shown immunogenicity and antiviral effects in mice. We performed a phase 1 clinical trial to assess safety and explore immunogenicity and early efficacy of TG1050 in CHB patients. This randomized, double blind, placebo-controlled study included two sequential phases: one single dose cohort (SD, n = 12) and one …

safetyHBsAg030231 tropical medicineImmunologyPlacebo-controlled studyPhases of clinical researchSciences du Vivant [q-bio]/Médecine humaine et pathologieimmunogenicityPlaceboAntiviral AgentsAdenoviridae03 medical and health sciencesMice0302 clinical medicineHepatitis B ChronicImmunogenicity VaccinevaccineImmunology and AllergyMedicineAnimalsHumans030212 general & internal medicineAdverse effectPharmacologyVaccinesHepatitis B Surface Antigens[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybusiness.industryELISPOTImmunogenicitychronicityimmuno-therapyHepatitis Bmedicine.diseaseHepatitis B3. Good healthImmunologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyResearch Paper
researchProduct